We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microsemi CRP Automated Hematology Analyzer Evaluated

By LabMedica International staff writers
Posted on 05 Feb 2015
Complete blood counts (CBC) including white blood cell count (WBC) differentials and C-reactive protein (CRP) have been frequently utilized as the biomarkers for inflammatory diseases such as bacterial infection. More...


An automated hematology analyzer has been developed which can simultaneously measure CBC including three-part WBC differential (3-Diff) and CRP using ethylenediaminetetraacetic acid dipotassium salt dihydrate (EDTA-2K) anticoagulated whole blood without centrifugation for serum preparation.

Scientists at HORIBA Medical (Kyoto, Japan) used the company’s automated hematology analyzer, The Microsemi CRP, which is equipped with the electrical resistance method for CBC with 3-Diff of granulocytes (GRA) including neutrophils eosinophils and basophils, lymphocytes (LYM), and monocytes (MON). CRP is measured with the latex immune turbidimetry method following the prompt hemolyzation of EDTA-2K anticoagulated whole blood. The obtained value is then converted into plasma concentration according to hematocrit (HCT %) of respective sample to finally provide as ‘whole blood CRP.’

Correlation tests for the Microsemi CRP were compared with those of Micros CRP200, a preceding Horiba Medical model, and also those of the ADVIA 2120i (Siemens; Munich, Germany) routine hematology analyzer. The results of fresh whole blood and serum CRP obtained using Micros CRP200 were compared with those of serum CRP obtained using HITACHI 7600 routine analyzer (Tokyo, Japan).

The CBC data examined using Microsemi CRP showed excellent correlation with the previous model, Micros CRP200and also those obtained using the routine analyzer, ADVIA 2120i. In regards to the 3-Diff, both GRA (%) and LYM (%) showed the excellent correlation coefficient between Microsemi CRP and Micros CRP200 as well as ADVIA 2120i. (MON (%) showed good correlation between Microsemi CRP and Micros CRP200, but lower correlation between Microsemi CRP and ADVIA 2120. CRP data showed the good correlation with HITACHI 7600 and Micros CRP200.

The authors concluded that Microsemi CRP was a convenient laboratory analyzer which could provide the clinically reliable data about CBC including 3-Diff and CRP using only 18 μL whole blood within approximately four minutes. Therefore, Microsemi CRP seemed suitable in the setting of point of care testing (POCT) for the patients with inflammatory diseases such as bacterial infection, especially for pediatric ones in whom sufficient volume of samples necessary to simultaneous measurement of CBC including WBC Diff and CRP using the routine analyzers. The study was first published online on December 11, 2014, in the International Journal of Laboratory Hematology.

Related Links:

HORIBA Medical
Siemens
HITACHI 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.